$APVO (Aptevo Therapeutics) — 8-K: Aptevo to present CD40-directed multispecific platform data at SITC 2026 Annual Meeting

Aptevo Therapeutics will present its CD40-directed multispecific portfolio at the SITC 2026 Annual Meeting, held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. The presentation, titled "Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity," is abstract number 1060 and will be delivered by Michelle Nelson, PhD. The platform is designed to combine tumor targeting with localized CD40 and T cell activation to engage innate and adaptive immunity within the tumor microenvironment while seeking to limit systemic immune activation. A copy of the presentation will be posted to the Publications page of the Aptevo website following the meeting.

Aptevo Therapeutics will present its CD40-directed multispecific portfolio at the SITC 2026 Annual Meeting, held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. The presentat